Format

Send to

Choose Destination
Pathol Res Pract. 2017 Dec;213(12):1552-1555. doi: 10.1016/j.prp.2017.09.012. Epub 2017 Sep 18.

PD-L1 expression in HNPCC-associated colorectal cancer.

Author information

1
Institute of Pathology, University of Cologne Medical School, Kerpener Str. 62, 50937, Cologne, Germany.
2
Institute of Pathology, University of Cologne Medical School, Kerpener Str. 62, 50937, Cologne, Germany. Electronic address: nicolaus.friedrichs@uk-koeln.de.

Abstract

BACKGROUND:

PD-L1 immunohistochemistry is predictive for molecular inhibitors of PD-1/PD-L1 immune checkpoint. Therefore, this study evaluated the PD-L1 expression in patients with Hereditary Non-Polyposis Colorectal Cancer (HNPCC).

METHODS:

Immunohistochemical expression of PD-L1 in carcinoma cells, stromal macrophages and lymphocytes of 40 HNPCC-patients with colorectal cancer was scored semi-quantitatively.

RESULTS:

Focal (2 cases) to extensive (2 cases) PD-L1-immunopositivity of carcinoma cells was detected in 4 out of 40 cases (10.0%). Stromal macrophages were immunopositive in 28 out of 40 cases (70.0%). Lymphocytes showed PD-L1 expression in 3 out of 40 cases (7.5%). Simultaneous immunopositivity of stromal macrophages and tumor cells was detected in two MLH1/PMS2-deficient and two MSH2/MSH6-deficient cases.

CONCLUSION:

A subset of HNPCC-associated colorectal cancers in this study clearly showed PD-L1 expression of tumor epithelia and immune cells, therefore, the detection of PD-L1 status is useful.

KEYWORDS:

Colorectal cancer; HNPCC; Lynch syndrome; Mismatch repair enzymes; PD-L1

PMID:
29033182
DOI:
10.1016/j.prp.2017.09.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center